Author:
Mostaghel Elahe A.,Nelson Peter S.
Reference121 articles.
1. Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med. 2004;10(1):33–9.
2. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol. 2005;23(32):8253–61.
3. de Bono JS. Abiraterone acetate improves survival in metastatic castration-resistant prostate cancer: phase III results. 2010 European Society for Medical Oncology, Milan, 2010.
4. Dreicer R, Agus DB, MacVicar GR, MacLean D, Zhang T, Stadler WM. Safety, pharmacokinetics, and efficacy of TAK-700 in castration-resistant, metastatic prostate cancer: a phase I/II, open-label study. Genitourinary cancers symposium, , San Francisco, Feb 2010.
5. Scher HI, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study. Lancet. 2010;375(9724):1437–46.